Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant, Abemaciclib, and Selinexor in Low Grade Serous Ovarian Cancer and Endometrioid Endometrial Cancer
NCT07832227Phase 2Not yet recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label trial of imlunestrant, abemaciclib and selinexor in Low grade serous ovarian cancer (LGSOC) and endometrioid endometrial cancer (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate up to 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
imlunestrantabemaciclibselinexor
03
Conditions
Low grade serous ovarian cancer (LGSOC)endometrioid endometrial cancer
Beyond the preview
Go deeper on NCT07832227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832227.